期刊文献+

人乳头瘤病毒16型病毒样颗粒的制备及其免疫原性研究 被引量:11

Production of Human Papillomavirus Type 16 Virus-like Particles and Its Immunogenicity
原文传递
导出
摘要 利用PCR技术从HPV16阳性阴道分泌物标本中获得HPV16 L1基因片段,并将其插入表达载体pTO-T7中,构建重组表达质粒pTO-T7-HPV16-L1;以该重组质粒转化大肠杆菌ER2566并表达HPV16 L1蛋白;所表达的HPV16 L1蛋白经过硫酸铵沉淀、离子交换层析和疏水相互作用层析等纯化步骤后,HPV16 L1纯度达到98%以上,并可在体外装配为直径50nm的病毒样颗粒;动物免疫原性研究结果显示,该病毒样颗粒可诱导高滴度的针对HPV16的中和抗体。上述研究结果表明通过大肠杆菌表达系统制备的HPV16病毒样颗粒具有纯度高,与天然病毒颗粒形态高度相似的特点,并具有高度免疫原性,可以应用于HPV16病毒样颗粒的结构功能研究及HPV16疫苗研发等领域。 HPV16 L1 gene was amplified from HPV16 positive vaginal secretion sample by PCR, and inserted into pTO-T7 to obtain the recombinant expression vector pTO-TT-HPV16-L1. Then, the pTO-TT- HPV16-L1 was transformed into E. coil strain ER2566 and the recombinant protein HPV16 L1 was expressed in soluble form. After purification by ammonium sulfate precipitation, ion-exchange chromatography, and hydrophobic interaction chromatography, the recombinant protein HPV16 L1 had a purity of more than 98%. By removing DTT, purified HPV16 L1 proteins self-assembled in vitro into VLPs with the diameter of 50nm. The vaccination experiments on experimental animals showed the VLPs could elicit high titer of neutralizing antibodies against HPV 16. HPV16 VLPs with high immunogenicity and high purity can be produced easily and effectively from an E. coli expression system in the study, and thus can be used in structure investigation and HPV16 vaccine development.
出处 《病毒学报》 CAS CSCD 北大核心 2009年第4期245-250,共6页 Chinese Journal of Virology
基金 国家自然科学基金(30600106 30500092) 国家工程中心技术研究建设项目(2005DC105006) 863计划重点项目(2006AA020905)
关键词 人乳头瘤病毒16型 大肠杆菌表达系统 纯化 病毒样颗粒 免疫原性 Human papillomavirus type 16 Escherichia coli expression system Purification Virus-like particle Immunogenicity
  • 相关文献

参考文献18

  • 1Insinga R P, Dasbach E J, Elbasha E H, et al. Incidence and duration of cervical human papillomavirus 6, 11, 16, and 18 infections in young women: an evaluation from multiple analytic perspectives[J]. Cancer Epidemiol Biomarkers Prey, 2007, 16(4):709-715.
  • 2Sterling J, Stanley M, Gatward G. Production of human papillomavirus type 16 virions in a keratinocyte cell line [J]. J Virol, 1990,64(12): 6305-6307.
  • 3Zhou J, Sun X Y, Stenzel D J, et al. Expression of vaccinia recombinant HPV 16 L1 and L2 ORF proteins in epithelial cells is sufficient for assembly of HPV virionlike particles[J]. Virology, 1991, 185(1): 251-257.
  • 4Kirnbauer R, Booy F, Cheng N, et al. PapiUomavirus L1 major capsid protein sell-assembles into virus-like particles that are highly immunogenic[J]. Proc Natl Acad Sci U S A, 1992,89(24) : 12180-12184.
  • 5Rose R C, Reichman R C, Bonnez W. Human papillamavirus (HPV) type Ⅱ recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol, 1994. 75 (Pt 8): 2075-2079.
  • 6Villa L L, Costa R. L, Petta C A, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase Ⅱ efficacy trial[J]. Lancet Oncol, 2005, 6 (5): 271-278.
  • 7Harper D M, Franco E L, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial[J]. Lancet, 2004, 364(9447) : 1757-1765.
  • 8潘晖榕,李少伟,刘波,朱子恒,曹欢欢,顾颖,程通,王颖彬,张军,夏宁邵.人乳头状瘤病毒6型类病毒颗粒的制备及其中和抗体的检测[J].中华微生物学和免疫学杂志,2009,29(1):71-76. 被引量:5
  • 9卢五迅,程通,李少伟,潘晖榕,沈文通,陈毅歆,张涛,郑舟,张军,夏宁邵.人乳头瘤病毒16型假病毒中和实验的建立和初步应用[J].生物工程学报,2006,22(6):990-995. 被引量:13
  • 10Banks L, Matlashewski G, Pim D, et al. Expression of human papillomavirus type 6 and type 16 capsid proteins in bacteria and their antigenic characterization[J]. J Gen Virol, 1987, 68 (Pt 12): 3081-3089.

二级参考文献42

  • 1卢五迅,程通,李少伟,潘晖榕,沈文通,陈毅歆,张涛,郑舟,张军,夏宁邵.人乳头瘤病毒16型假病毒中和实验的建立和初步应用[J].生物工程学报,2006,22(6):990-995. 被引量:13
  • 2萨姆布鲁克J 金冬雁等(译).分子克隆操作指南(第2版)[M].北京:科学出版社,1992..
  • 3朱玉贤 李毅.现代分子生物学[M].北京:高等教育出版社,1998.195.
  • 4Baseman JG, Koutsky LA. The epidemiology of human papillomavirus infections. J Clin Virol, 2005, 32 ( Suppl 1 ) : S16-24.
  • 5Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med, 1997, 102(5A) : 3-8.
  • 6Zhou J, Sun XY, Stenzel D J, et al. Expression of vaccinia recombinant HPV 16 L1 and L20RF proteins in epithelial cells is sufficient for assembly of HPV virion-like particles. Virology, 1991,185(1): 251-257.
  • 7Ruiz W, Mcclements WL, Jansen KU, et al. Kinetics and isotype profile of antibody responses in rhesus macaques induced following vaccination with HPV 6, 11, 16 and 18 Ll-virus-like particles formulated with or without Merck aluminum adjuvant. J Immune Based Ther Vaccines, 2005, 3 ( 1 ) : 2.
  • 8Villa LL, Costa RL Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer, 2006, 95( 11 ) : 1459-1466.
  • 9Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet, 2004, 364(9447) : 1757-1765.
  • 10Rose RC, Reichman RC, Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol, 1994, 75 ( Pt 8) : 2075- 2079.

共引文献45

同被引文献162

  • 1郝东风,马正海,王艳萍,热西旦,张富春.HPV16 L1基因的原核表达及免疫反应性鉴定[J].细胞与分子免疫学杂志,2005,21(4):428-431. 被引量:3
  • 2卢五迅,程通,李少伟,潘晖榕,沈文通,陈毅歆,张涛,郑舟,张军,夏宁邵.人乳头瘤病毒16型假病毒中和实验的建立和初步应用[J].生物工程学报,2006,22(6):990-995. 被引量:13
  • 3Zui Hausen H. Papillomaviruses in anogenital cancer as a model to understand the role of viruses in human cancers. Cancer Res, 1989,49:4677.
  • 4Schiller JT, Castellsague X, Villa LL, et al. An update of prophylactic human papillomavirusLI virus like particle vaccine clinical trial results. Vaccine,2008,19 ;53-61.
  • 5项铮.我国宫颈癌疫苗研制有望成世界第三.科技日报,2011年2月17日.
  • 6Kawana K, Matsumoto K, Yoshikawa H, et al. A surface immunodeterminant of human PV type 16 minor capsid protein L2. Viroloyg,1998,245 :353-359.
  • 7Kawana K, Yoshikawa H, Taketani Y, et al. Common neutralization epitone in minor protein L2 of human PV types 16 and 6. Viroloyg, 1999,73:6188-6190.
  • 8Gambhlra R, Karanam B, Jagu S, ct al. A protective and broadly cross-neutralizing epitope of human PV L2. Virology, 2007,81 : 13927-13931.
  • 9Jagu S, Karanam B, Gambhira R, et al. Concatenated muhitype L2 fusion proteins candidate prophylactic pan-human papillomavirus vaccines. J Natl Cancer Inst,2009,101 : 782-792.
  • 10Rubio I, Bolchi A, Moretto N, et al. Potent anti-HPV immune responses induced by tandem repeats of the HPV16 1-2 ( 20-38 ) peptide displayed on bacterial thioredoxin. Vaccine, 2009,27: 1949-1956.

引证文献11

二级引证文献31

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部